--- title: 'Clinical Daily Summary: What Happened on October 11, 2026' headline: Prime Medicine starts Wilson disease trial as Birmingham asthma service cuts waits description: Prime dosed the first participant in a Wilson disease study. A hospital-Sanofi project increased severe-asthma biologic starts and reduced waits. url: https://thebench.bio/news/clinical/2026-10-11 topic: clinical date: '2026-10-11' covers: - '2026-10-10' - '2026-10-11' date_published: '2026-10-11T12:01:01Z' date_modified: '2026-10-11T12:01:01Z' sources: 3 publisher: The Bench (thebench.bio) --- # Clinical Daily Summary: What Happened on October 11, 2026 **Prime Medicine starts Wilson disease trial as Birmingham asthma service cuts waits** Prime dosed the first participant in a Wilson disease study. A hospital-Sanofi project increased severe-asthma biologic starts and reduced waits. ## Today in brief A participant has received Prime Medicine’s PM577a in a global Phase I/II trial for Wilson disease caused by the H1069Q mutation. [1] At University Hospitals Birmingham, severe-asthma biologic starts rose from 51 to 174 across comparable 12-month periods after a Sanofi partnership project, while average waits fell from 196 days to 103. [2] ProAxsis and Imperial College London are studying a rapid test for active neutrophil elastase during COPD exacerbations, with results expected in 2027. [3] ## Prime Medicine starts dosing in Wilson disease study Prime Medicine has dosed the first participant in a global Phase I/II study of PM577a for Wilson disease caused by the H1069Q mutation. [1] Allen Reine expects clinical results from this program and Prime’s alpha-1 antitrypsin deficiency liver program in 2027. [1] ## Birmingham project increased asthma biologic starts Biologic treatment starts for severe asthma rose from 51 to 174 in comparable 12-month periods before and after University Hospitals Birmingham and Sanofi’s service project. [2] Over the same comparison, average waits to start treatment fell from 196 days to 103. [2] The partners funded an administrator to manage the biologics database, coordinate care and simplify patients’ routes to treatment. [2] The service added a weekly biologic clinic. Within five months of the administrator starting, the Trust approved a business case to retain the role. [2] ## COPD study tests rapid biomarker assay during exacerbations ProAxsis and Imperial College London are evaluating a rapid point-of-care test for active neutrophil elastase in people experiencing chronic obstructive pulmonary disease (COPD) exacerbations. [3] The 21-month collaboration is assessing whether the test can help identify what is driving an exacerbation, which symptoms alone may not reveal. [3] The study’s results are expected in 2027. [3] In a separate UK randomized trial, point-of-care C-reactive protein testing during COPD exacerbations reduced antibiotic use without worsening COPD health status. [3] ## Also worth knowing - Japan’s PMDA accepted Nanoscope Therapeutics’ MOGENRY for priority review for inherited retinal dystrophies, with supporting data in retinitis pigmentosa and Stargardt disease. [1] - Cellares executive Fabian Gerlinghaus estimated that losing Bristol Myers Squibb’s manufacturing agreement could delay commercial production by about a year. The FDA selected Cellares for its PreCheck program. [1] ## The day in numbers - **174 vs. 51**: Severe-asthma patients who started biologic treatment in 12-month periods after and before the Birmingham project. [2] - **103 vs. 196 days**: Average wait to start biologic treatment after and before the project. [2] ## Also published - [Five Facts about COPD](), Pharmafile ## Sources 1. [Reporter’s Notebook: Cell and Gene Therapy’s Success Lies Beyond the Bespoke (Part 1)](), Inside Precision Medicine, 2026-10-10 2. [Excellence in Healthcare Partnership Awards – A Collaborative Working Project Between Sanofi and The University Hospital Birmingham Severe Asthma Team](), Pharmafile, 2026-10-11 3. [How will biomarker-led diagnostics reshape respiratory medicine?](), Pharmafile, 2026-10-11 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: